Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

Executive Chair Chung emphasizes customer-focused transformation and ecosystem strengthening to navigate evolving market ...

An important work from a rediscovered artist has been absent from public view since the 1970s. A New York curator is hunting ...

Key PointsMarathon Petroleum Corporation (MPC) was named to the Women In Trucking Association's 2025 Top Companies for Women ...

While standard operating procedures in Part 91 may be voluntary, adopting them is a critical step in professionalizing your ...

It has been an especially full and public December for King Frederik, Queen Mary, and their four children, Crown Prince ...

Air Peace to resume Ibadan–Abuja flights Dec 24SCHEDULED commercial flights between Ibadan and Abuja have resumed, with Air Peace set to commence operations on Wednesday, December 24. Residents can ...

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...

In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...

Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...

Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...